Malaysia | Amsterdam | 17 January 2020 | Intran Technologies inked a collaboration with Leader Biomedical, the renowned Netherlands based medical devices group in establishing the region’s first private-initiated human tissue processing facility in Malaysia. This partnership follows the 2015 establishment of a joint venture between these parties, Leader Biomedical Asia Pacific Sdn Bhd, headquartered in Petaling Jaya as the regional South East Asian sales and marketing office.

The goal of this collaboration is to establish a manufacturing facility that would provide safe, effective and novel human allografts, processed using the best-in-class supercritical CO2 extraction techniques, that would significantly improve the post-operative quality of life of orthopedic, dental, spine and trauma patients in Malaysia and the SEA region. Working towards this collaboration to establish an intelligent alliance in business interaction, cooperative development and other forms of specialized collaborations, Intran Technologies has been working closely with the Ministry of Health, the National Transplant Resource Centre and with the relevant regulatory authorities to start a one-of-a-kind regional Human Tissue Processing Centre in Malaysia.

This centre will utilize the  eCOO® Technology Platform, Leader Biomedical’s unique proprietary solution to clean, sterilize and impregnate human and animal-derived tissues using supercritical carbon dioxide (scCO2), which has been validated, used and registered in EU since 2004. Leader Biomedical and Intran Technologies have established an active partnership with Koperasi Pusat Perubatan Universiti Malaysia Bhd (KPPUMB) as the strategic investor to plan, construct and maintain a regional Human Tissue Processing Centre in Malaysia.

With the signing ceremony of the Memorandum of Understanding (MOU), the three companies will bring ownership, experience and investment in the establishment of this Tissue Processing Centre in Malaysia.  Encik Hanifah bin Abdlah, Chairman of KPPUMB signed on behalf of the cooperative while Leader Biomedical Europe Holding BV, The Netherlands was represented by its Group Business Director, Mr. Basil Babychan and Intran Technologies was represented by the Managing Director, Mr. Padmanabhan Mahalingam. The main aim of this MOU is to provide mutual benefits to both parties and to focus on taking concrete step towards establishing solid Tissue Graft and expose the patients to recuperate fast from the post-operative life.

With the MOU in place, Leader Biomedical together with Intran Technologies have pursued another milestone today with the signing of a Letter of Intent (LOI) between Universiti Kebangsaan Malaysia’s Tissue Engineering Centre (TEC) under the Faculty of Medicine known for its remarkable research and development competencies in producing top class ‘biological grafts’ for utilizing eCOO® Technology in the world of regenerative medicine.

The Letter of Intent was signed by both Mr. Basil Babychan and Mr. Padmanabhan on behalf of their organizations respectively and Y Bhg Professor Dato’ Dr Ruszymah Hj Idrus, Head of Tissue Engineering Centre signed on behalf of Faculty of Medicine, Universiti Kebangsaan Malaysia. This collaboration with the Tissue Engineering Centre, Faculty of Medicine of Universiti Kebangsaan Malaysia is intended to generate a pipeline of sustainable and innovative products and process applications. The aim is to apply and further develop eCOO® Technology for cardiovascular, neurological and general surgery applications with improved product features and superior process characteristics. The letter of intent outlines a strategic cooperation between the three parties on utlizing the manufacturing facility to be the hub for research and development as well as training in new tissue processing methods. It would also be the first in the region to utilize Leader Biomedical’s proprietary eCOO® Technology platform that utilizes supercritical fluid technology for the acellularisation and delipidation of biological tissue from animal and human sources. Allografts are used in various medical procedures such as in accidents and similar trauma cases when there is bone loss or soft tissue damage.The processed tissues can also be used in wound care like diabetic wound to regenerate the skin, in dental care such as for cases of tooth decay, spine care, as well as in sports injury as in tendon and ligament repair.

About Leader Biomedical:
Leader Biomedical Europe Holding B.V. (LBEH), via its wholly owned subsidiaries Leader Biomedical Europe BV (LBE) and EMCM B.V manufactures and distributes biomaterials and implantable medical devices. While the subsidiary EMCM has been in active operations since 1993, the group holding company was founded in 2014 and is headquartered in Amsterdam, the Netherlands.
Leader Biomedical is committed to extending the reach of patients and caregivers worldwide. We do this by marketing and distributing medical devices, developing new technologies, and delivering world-class contract manufacturing. Leader Biomedical specialises in marketing and distributing targeted therapeutic solutions for dental, spine, joint care, and sports medicine indications (www.leaderbiomedical.com).

About Intran Technologies Sdn Bhd (ITSB)
Intran Technologies Sdn. Bhd. is a specialist in the design and construction of GMP/GTP compliant facilities for regenerative medicine. It is the joint venture partner of Leader Biomedical Asia Pacific, the regional sales and marketing operation of Leader Biomedical Europe for the ASEAN region. (www.intrantechnologies.com.)